ProQR Therapeutics N.V. (PRQR) Receives Consensus Recommendation of “Buy” from Analysts
Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned a consensus rating of “Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $16.38.
Several brokerages recently commented on PRQR. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a research note on Tuesday, June 20th. Zacks Investment Research upgraded shares of ProQR Therapeutics N.V. from a “sell” rating to a “hold” rating in a research note on Wednesday, May 3rd.
A number of large investors have recently made changes to their positions in PRQR. Janus Henderson Group PLC bought a new stake in shares of ProQR Therapeutics N.V. during the second quarter valued at approximately $2,028,000. Artal Group S.A. raised its position in ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 100,000 shares in the last quarter. Sphera Funds Management LTD. raised its position in ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after buying an additional 130,000 shares in the last quarter. Finally, Hikari Power Ltd acquired a new position in ProQR Therapeutics N.V. during the first quarter worth approximately $121,000. Hedge funds and other institutional investors own 35.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/15/proqr-therapeutics-n-v-prqr-receives-consensus-recommendation-of-buy-from-analysts.html.
ProQR Therapeutics N.V. (PRQR) opened at 4.90 on Tuesday. ProQR Therapeutics N.V. has a 52-week low of $3.65 and a 52-week high of $8.70. The firm’s market capitalization is $116.94 million. The company has a 50 day moving average price of $5.15 and a 200 day moving average price of $4.80.
ProQR Therapeutics N.V. (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, May 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.02. On average, equities analysts forecast that ProQR Therapeutics N.V. will post ($2.20) EPS for the current fiscal year.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.